Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Anti–Factor Xa Activity and Percent Change from Baseline in Patients Receiving Rivaroxaban and Apixaban (Efficacy Population). Shown are the values for anti–factor Xa activity (as measured by means of a validated chromogenic assay of factor Xa enzymatic activity) and the percent change from baseline in patients with acute major bleeding who received andexanet to counteract the anticoagulant effects of rivaroxaban or apixaban.
In randomized clinical trials, factor Xa inhibitors have been shown to be safe and effective for the treatment and prevention of venous thromboembolism and for stroke prevention in patients with atrial fibrillation. 1-4 However, factor Xa inhibitors have been associated with major and even fatal bleeding events. 1-4 Such episodes of acute major bleeding may be difficult to treat because there is no reversal agent.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
